• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PARP抑制后复制诱导的DNA损伤会导致G2期延迟,以及细胞系依赖性的凋亡、坏死和多核化。

Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.

作者信息

Dale Rein Idun, Solberg Landsverk Kirsti, Micci Francesca, Patzke Sebastian, Stokke Trond

机构信息

a Group for Molecular Radiation Biology ; Department of Radiation Biology ; The Norwegian Radium Hospital ; Oslo , Norway.

b Section of Cancer Cytogenetics, Institute for Medical Informatics, The Norwegian Radium Hospital ; Oslo , Norway.

出版信息

Cell Cycle. 2015;14(20):3248-60. doi: 10.1080/15384101.2015.1085137.

DOI:10.1080/15384101.2015.1085137
PMID:26312527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4825575/
Abstract

PARP inhibitors have been approved for treatment of tumors with mutations in or loss of BRCA1/2. The molecular mechanisms and particularly the cellular phenotypes resulting in synthetic lethality are not well understood and varying clinical responses have been observed. We have investigated the dose- and time-dependency of cell growth, cell death and cell cycle traverse of 4 malignant lymphocyte cell lines treated with the PARP inhibitor Olaparib. PARP inhibition induced a severe growth inhibition in this cell line panel and increased the levels of phosphorylated H2AX-associated DNA damage in S phase. Repair of the remaining replication related damage caused a G2 phase delay before entry into mitosis. The G2 delay, and the growth inhibition, was more pronounced in the absence of functional ATM. Further, Olaparib treated Reh and Granta-519 cells died by apoptosis, while U698 and JVM-2 cells proceeded through mitosis with aberrant chromosomes, skipped cytokinesis, and eventually died by necrosis. The TP53-deficient U698 cells went through several rounds of DNA replication and mitosis without cytokinesis, ending up as multinucleated cells with DNA contents of up to 16c before dying. In summary, we report here for the first time cell cycle-resolved DNA damage induction, and cell line-dependent differences in the mode of cell death caused by PARP inhibition.

摘要

聚(ADP - 核糖)聚合酶(PARP)抑制剂已被批准用于治疗具有BRCA1/2突变或缺失的肿瘤。导致合成致死性的分子机制,尤其是细胞表型,目前尚不清楚,并且已观察到不同的临床反应。我们研究了用PARP抑制剂奥拉帕尼处理的4种恶性淋巴细胞系的细胞生长、细胞死亡和细胞周期进程的剂量和时间依赖性。PARP抑制在该细胞系组中诱导了严重的生长抑制,并增加了S期磷酸化H2AX相关DNA损伤的水平。对剩余复制相关损伤的修复导致进入有丝分裂前的G2期延迟。在缺乏功能性ATM的情况下,G2期延迟和生长抑制更为明显。此外,奥拉帕尼处理的Reh和Granta - 519细胞通过凋亡死亡,而U698和JVM - 2细胞经历有丝分裂,染色体异常,跳过胞质分裂,最终坏死死亡。TP53缺陷的U698细胞在没有胞质分裂的情况下经历了几轮DNA复制和有丝分裂,最终成为多核细胞,其DNA含量高达16c,然后死亡。总之,我们首次在此报告了细胞周期解析的DNA损伤诱导以及PARP抑制引起的细胞死亡模式的细胞系依赖性差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/c5d1ba864165/kccy-14-20-1085137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/6f44fdb4ef7e/kccy-14-20-1085137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/bfa1046c5b6c/kccy-14-20-1085137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/bd9248d3fb6c/kccy-14-20-1085137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/ae1108f9ba8c/kccy-14-20-1085137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/fb389abfb119/kccy-14-20-1085137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/5a58f45fbea2/kccy-14-20-1085137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/c5d1ba864165/kccy-14-20-1085137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/6f44fdb4ef7e/kccy-14-20-1085137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/bfa1046c5b6c/kccy-14-20-1085137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/bd9248d3fb6c/kccy-14-20-1085137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/ae1108f9ba8c/kccy-14-20-1085137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/fb389abfb119/kccy-14-20-1085137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/5a58f45fbea2/kccy-14-20-1085137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a20/4825575/c5d1ba864165/kccy-14-20-1085137-g007.jpg

相似文献

1
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.PARP抑制后复制诱导的DNA损伤会导致G2期延迟,以及细胞系依赖性的凋亡、坏死和多核化。
Cell Cycle. 2015;14(20):3248-60. doi: 10.1080/15384101.2015.1085137.
2
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX.由γH2AX水平定义的细胞周期G2期新的不同区室。
Cell Cycle. 2015;14(20):3261-9. doi: 10.1080/15384101.2015.1087617.
3
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.ATR 抑制诱导的过早有丝分裂进入增强了 BRCA2 缺陷型癌细胞中奥拉帕利抑制介导的基因组不稳定性、炎症信号和细胞毒性。
Mol Oncol. 2019 Nov;13(11):2422-2440. doi: 10.1002/1878-0261.12573. Epub 2019 Oct 21.
4
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.奥拉帕利联合 AZD1775 通过破坏 DNA 损伤修复途径和 DNA 损伤检查点增强胃癌的抗肿瘤活性。
J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7.
5
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.新型抑制剂西咪帕尼的聚(ADP - 核糖)聚合酶(PARP)抑制作用及抗癌活性,该抑制剂正在进行临床试验。
Cancer Lett. 2017 Feb 1;386:47-56. doi: 10.1016/j.canlet.2016.11.010. Epub 2016 Nov 12.
6
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.三阴性乳腺癌中聚(ADP-核糖)聚合酶(PARP)和组蛋白去乙酰化酶(HDAC)的联合靶向治疗:BRCA 突变细胞中更高的协同作用。
Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
7
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.奥拉帕利调节 DNA 修复效率,使宫颈癌细胞对顺铂敏感,并表现出抗转移特性。
Sci Rep. 2017 Oct 9;7(1):12876. doi: 10.1038/s41598-017-13232-3.
8
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.组蛋白去乙酰化酶抑制剂,辛二酰苯胺异羟肟酸(SAHA),增强了聚(ADP - 核糖)聚合酶(PARP)抑制剂奥拉帕尼在三阴性乳腺癌细胞中的抗肿瘤作用。
Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.
9
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.WIP1 促进同源重组并调节对 PARP 抑制剂的敏感性。
Cells. 2019 Oct 15;8(10):1258. doi: 10.3390/cells8101258.
10
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.Rad51降解:在胶质母细胞瘤溶瘤病毒-聚(ADP-核糖)聚合酶抑制剂联合治疗中的作用
J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.

引用本文的文献

1
N4-acetylcytidine and other RNA modifications in epitranscriptome: insight into DNA repair and cancer development.表观转录组中的N4-乙酰胞苷及其他RNA修饰:对DNA修复和癌症发展的见解
Epigenomics. 2025 Apr;17(6):411-422. doi: 10.1080/17501911.2025.2473308. Epub 2025 Mar 5.
2
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.在 RB1 缺陷型癌细胞中,针对复制扰乱治疗药物的合成致死依赖性依赖于酪蛋白激酶 2。
Sci Adv. 2024 May 24;10(21):eadj1564. doi: 10.1126/sciadv.adj1564. Epub 2024 May 23.
3
Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.

本文引用的文献

1
Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.p53在四倍体癌细胞的产生和靶向中的新作用。
PLoS One. 2014 Nov 7;9(11):e110844. doi: 10.1371/journal.pone.0110844. eCollection 2014.
2
5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair.5-氮杂-2'-脱氧胞苷导致需要范可尼贫血相关同源重组修复的复制损伤。
Nucleic Acids Res. 2013 Jun;41(11):5827-36. doi: 10.1093/nar/gkt270. Epub 2013 Apr 22.
3
RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Rho 激酶(ROCK)抑制剂在 BRCA2 缺陷细胞中诱导多种有丝分裂缺陷和合成致死。
Elife. 2023 Apr 19;12:e80254. doi: 10.7554/eLife.80254.
4
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.抑制烟酰胺腺嘌呤二核苷酸补救途径可克服高级别浆液性卵巢癌中的获得性和内在多聚(ADP-核糖)聚合酶抑制剂耐药性。
Sci Rep. 2023 Feb 27;13(1):3334. doi: 10.1038/s41598-023-30081-5.
5
Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells.二氢卟吩增强奥沙利铂和阿霉素对肝癌细胞的抗癌作用。
J Pers Med. 2022 Aug 16;12(8):1318. doi: 10.3390/jpm12081318.
6
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.上皮性卵巢癌的当前治疗方法及新的潜在辅助治疗手段
Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077.
7
Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines.二甲双胍通过诱导上皮性卵巢癌细胞系凋亡影响奥拉帕利敏感性。
Int J Mol Sci. 2021 Sep 29;22(19):10557. doi: 10.3390/ijms221910557.
8
Alternative models of cancer stem cells: The stemness phenotype model, 10 years later.癌症干细胞的替代模型:干性表型模型,十年之后。
World J Stem Cells. 2021 Jul 26;13(7):934-943. doi: 10.4252/wjsc.v13.i7.934.
9
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.他拉唑帕利与帕博西尼联合使用作为膀胱癌的有效治疗策略
J Pers Med. 2021 Apr 24;11(5):340. doi: 10.3390/jpm11050340.
10
The SC-35 Splicing Factor Interacts with RNA Pol II and A-Type Lamin Depletion Weakens This Interaction.SC-35 剪接因子与 RNA 聚合酶 II 相互作用,A 型层粘连蛋白缺失会削弱这种相互作用。
Cells. 2021 Feb 1;10(2):297. doi: 10.3390/cells10020297.
RAD51C 缺陷型癌细胞对 PARP 抑制剂奥拉帕尼高度敏感。
Mol Cancer Ther. 2013 Jun;12(6):865-77. doi: 10.1158/1535-7163.MCT-12-0950. Epub 2013 Mar 19.
4
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.临床 PARP 抑制剂对 PARP1 和 PARP2 的捕获。
Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.
5
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.基于跨平台通路分析鉴定出对 PARP 抑制剂奥拉帕利应答的标志物。
Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.
6
Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase.辐射诱导的双链断裂需要 ATM,但在 S 期进行同源重组时不需要 Artemis。
Nucleic Acids Res. 2012 Sep 1;40(17):8336-47. doi: 10.1093/nar/gks604. Epub 2012 Jun 22.
7
Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.Mre11 依赖性的停滞 DNA 复制叉降解被 BRCA2 和 PARP1 所阻止。
Cancer Res. 2012 Jun 1;72(11):2814-21. doi: 10.1158/0008-5472.CAN-11-3417. Epub 2012 Mar 23.
8
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.同时存在 ATM 和 p53 突变的套细胞淋巴瘤中,聚腺苷二磷酸核糖聚合酶抑制剂的细胞毒性增强。
EMBO Mol Med. 2012 Jun;4(6):515-27. doi: 10.1002/emmm.201200229. Epub 2012 Mar 13.
9
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.评估奥拉帕利联合贝伐珠单抗治疗晚期实体瘤患者的安全性和耐受性的 I 期研究。
Br J Cancer. 2012 Jan 31;106(3):468-74. doi: 10.1038/bjc.2011.555. Epub 2012 Jan 5.
10
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.抑制多聚(ADP-核糖)聚合酶(PARP)和共济失调毛细血管扩张突变(ATM)可提高套细胞淋巴瘤对诱导 DNA 链断裂药物的敏感性。
Hematol Oncol. 2012 Dec;30(4):175-9. doi: 10.1002/hon.1020. Epub 2011 Dec 14.